Select your language
OTHER WORKGROUPS
SEFH HOME PAGE
GEDEFO
Who are we?
Mission
Regulations
Members
CONSENSUS STATEMENTS AND POSITION PAPERS
10 COMMON CHALLENGES FACED BY HOSPITAL PHARMACY AND ONCOLOGY UNITS (2021)
CLINICAL INTERVIEW
2021-2025 STRATEGIC PLAN
RED C (C NETWORK) (2021)
THE CMO MODEL FOR CANCER AND HEMATOLOGICAL PATIENTS (2020)
SEFH’S POSITION PAPER ON THE NEW ANTINEOPLASTIC MEDICATIONS (2019)
CAR-T CELL THERAPY MANAGEMENT PROCEDURE (2019)
PHARMACEUTICAL VALIDATION OF MEDICAL PRESCRIPTIONS FOR HEMATO-ONCOLOGICAL PATIENTS (2018)
SEFH’S POSITION PAPER ON BIOSIMILAR DRUGS (2017)
STRATEGIC PLAN ON THE PHARMACEUTICAL CARE OF HEMATO-ONCOLOGICAL PATIENTS (2016)
POSITION PAPER ON THE ACCESS TO NEW ANTINEOPLASTIC MEDICATION (2015)
CONSENSUS STATEMENTS
COMPASSIONATE USE OF DRUGS
MEDICATION ERRORS
ORAL MEDICATION
DOCUMENTS
PATIENT INFORMATION
MEDICATION: INFORMATIONAL LEAFLETS
SUPPORT MATERIALS
ORAL PEDIATRIC MEDICATION
COLORRECTAL CANCER PROCEDURES
CHEMOTHERAPY: COLLATERAL EFFECTS
CHEMOTHERAPY MANAGEMENT PROTOCOLS
EXTRAVASATION AND EFFUSIONS
COLORRECTAL CANCER PROTOCOLS - NURSING
DISEASE MONOGRAPHS
EXTRAVASATION MONOGRAPHS
WHAT IS A BIOSIMILAR DRUG? (GTEII)
BRIEFING NOTES
LINKS OF INTEREST
GEDEFO PUBLISHING REGULATIONS
PUBLICATIONS
EDUCATIONAL ACTIVITIES
JOIN OUR WORKGROUP
Contact us
Search
SEFH’S POSITION PAPER ON THE NEW ANTINEOPLASTIC MEDICATIONS (2019)
Details
DESCARGA EL DOCUMENTO AQUÍ
FOLLOW US ON X
gedefo_sefh
Instagram
GEDEFO CARES
GEDEFO CARES
TOOLS
CALCULATORS
MOBILE APPS
NEWSLETTERS
PAST NEWSLETTERS
ESOP
EUROPEAN SOCIETY OF ONCOLOGY PHARMACY
EBMT
EUROPEAN SOCIETY FOR BLOOD AND MARROW TRANSPLATATION
BPS PROJECT
BPS PROJECT
